Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder

TitleRandomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder
Publication TypeJournal Article
Year of Publication2010
AuthorsThurstone, C, Riggs, PD, Salomonsen-Sautel, S, Mikulicn-Gilbertson, SK
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume49
Pagination573-582
PublisherLippincott Williams & Wilkins
Place PublishedUS
Publication Languageeng
ISBN Number0890-85671527-5418
Accession Number2010-11929-006. First Author & Affiliation: Thurstone, Christian
Keywordsadolescents, atomoxetine, Attention Deficit Disorder with Hyperactivity, attention deficit hyperactivity disorder, clinical trials, cognitive behavior therapy, Cognitive behavioral therapy, controlled trials, Drug abuse, motivational interviewing, Placebo, substance use disorder
Abstract

Objective: To evaluate the effect of atomoxetine hydrochloride versus placebo on attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) in adolescents receiving motivational interviewing/cognitive behavioral therapy (MI/CBT) for SUD. Method: This single-site, randomized, controlled trial was conducted between December 2005 and February 2008. Seventy adolescents (13 through 19 years of age) with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) ADHD, a DSM-IV ADHD checklist score greater than or equal to 22, and at least one nontobacco SUD were recruited from the community. All subjects received 12 weeks of atomoxetine hydrochloride + MI/CBT versus placebo + MI/CBT. The main outcome measure for ADHD was self-report DSM-IV ADHD checklist score. For SUD, the main outcome was self-report number of days used nontobacco substances in the past 28 days using the Timeline Followback interview. Results: Change in ADHD scores did not differ between atomoxetine + MI/CBT and placebo + MI/CBT (F4,191 = 1.23, p = .2975). Change in days used nonnicotine substances in the last 28 days did not differ between groups (F3,100 = 2.06, p = .1103). Conclusions: There was no significant difference between the atomoxetine + MI/CBT and placebo + MI/CBT groups in ADHD or substance use change. The MI/CBT and/or a placebo effect may have contributed to a large treatment response in the placebo group. (PsycINFO Database Record (c) 2010 APA, all rights reserved) (journal abstract)

URLhttp://libproxy.unm.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-11929-006&login.asp&site=ehost-live&scope=siteChristian.Thurstone@dhha.org
Language: 
English
Go to top